Workshop for implementing support tools to promote safety in the prescribing of oral contraceptives
实施支持工具以促进口服避孕药处方安全的讲习班
基本信息
- 批准号:10742446
- 负责人:
- 金额:$ 5.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptionComputer softwareContraceptive AgentsContraceptive methodsDataEducational workshopEligibility DeterminationFeedbackFutureGrantHealth Services AccessibilityHealthcare SystemsInnovation CorpsKnowledgeMedical TechnologyMedicineModificationOral ContraceptivesPaperPharmacistsPharmacy facilityPhasePopulationPregnancy RateProcessSafetyServicesSmall Business Innovation Research GrantSystemTechnologyTestingTimeUnited StatesWomancombatcommercializationdesignhealth inequalitiesimprovedinsightinterestmemberpatient safetyprogramsrecruitsupport toolsunintended pregnancyusability
项目摘要
SUMMARY
The overall objective of our predicate SBIR Phase I grant, which commenced in September 2022, is to
investigate the feasibility of pharmacists utilizing our proprietary OvaryIt software to prescribe contraceptives.
Many states allow pharmacists to prescribe contraception, but the current paper-based process is inefficient
and difficult to incorporate into daily practice for busy pharmacists. Therefore, even though many pharmacists
are eligible to prescribe contraceptives, very few are actively offering these services. There continues to be an
ongoing need for access to contraceptive services in the United States (US), with approximately 19 million
women living in what is deemed a contraceptive desert. Because 90% of the population lives within 5 miles of
a pharmacy, pharmacist-prescribed contraceptive services have the potential to dramatically increase access
to care, decrease inequities in the health care system, and combat the high unintended pregnancy rate in the
US.
During Phase I, the OvaryIt Team has begun networking with numerous pharmacists with diverse backgrounds
from across the US to gather insights and data. In addition to the primary feasibility objective, the team has
recruited subject matter experts to assist in the creation of a comprehensive implementation package that
addresses the barriers to the adoption of pharmacist-prescribed contraceptive services, determine the
technological and operational requirements needed to successfully incorporate the solution into existing
pharmacy workflows, and conduct usability testing to guide incremental improvements to the OvaryIt software.
Early findings support our hypothesis that pharmacists are interested in providing contraceptive services, and
they perceive that utilizing the OvaryIt software increases efficiency, patient safety, and the feasibility of
incorporating contraceptive services into daily practice. Additionally, we received valuable feedback regarding
potential modifications to the user interface that will guide improvements in the future system.
OvaryIt, LLC has assembled a strong team with expertise in project management, contraceptive medicine, and
medical technology design and implementation. All three members are committed to the time requirements of
the program. The OvaryIt Team is willing to modify, adapt, and refine the overall commercialization strategy
based on knowledge gained during the I-Corps Program.
总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Devin Bustin其他文献
Devin Bustin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 5.4万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 5.4万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 5.4万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 5.4万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 5.4万 - 项目类别:
Standard Grant














{{item.name}}会员




